Shopping Cart
Remove All
Your shopping cart is currently empty
Xentuzumab
Copy Product Info
😃Good
Catalog No. T76795Cas No. 1417158-65-6
Alias BI 836845
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
Xentuzumab
Copy Product Info😃Good
Purity: 95.21%
Catalog No. T76795Alias BI 836845Cas No. 1417158-65-6
Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $347 | In Stock | In Stock | |
| 5 mg | $886 | In Stock | In Stock | |
| 10 mg | $1,450 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:95.21%
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Xentuzumab (BI836845) is a recombinant monoclonal antibody to humanised IGF ligand that inhibits IGF1 and IGF2 growth-promoting signalling and inhibits AKT activation for the study of solid tumours. |
| In vitro | After 5 or 10 days of incubation, single-agent Xentuzumab(XENT)or ENZA reduced the viability of VCaP, DuCaP, and MDA PCa 2b cells in a dose-dependent manner. Combination therapy further decreased cell viability compared to monotherapy; likewise, treatment with XENT+ENZA resulted in a significant reduction in the expression of cell cycle genes, ubiquitin-conjugating enzyme E2 C (UBE2C), cyclin-dependent kinase 1 (CDK1), and cell division cycle protein 20 (CDC20) compared to single-agent treatment.[1]. |
| In vivo | Monotherapy with ENZA did not inhibit tumor growth. However, the addition of Xentuzumab(XENT)rendered the tumors sensitive to ENZA again, leading to a significant reduction in tumor volume[1]. |
| Synonyms | BI 836845 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IGF-1 |
| Molecular Weight | 143.7 kDa |
| Cas No. | 1417158-65-6 |
| Isotype | Human IgG1 lambda C2 |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Xentuzumab | purchase Xentuzumab | Xentuzumab cost | order Xentuzumab | Xentuzumab chemical structure | Xentuzumab in vivo | Xentuzumab in vitro | Xentuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.